RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome)

NCT07236606 · clinicaltrials.gov ↗
PHASE3
Phase
SUSPENDED
Status
2
Enrollment
INDUSTRY
Sponsor class

Stopped The FDA placed a clinical hold on RGX-121, for the treatment of MPSII, following the report of a single case of neoplasm (intraventricular CNS tumor) in a participant treated with RGX-111 for the treatment of MPSI four years prior.

Conditions

Interventions

Sponsor

REGENXBIO Inc.